Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser
A Multi-center, Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser for the Tolerability and Improvement in the Appearance of Aging Skin.
Lynch Regenerative Medicine
21 participants
Apr 16, 2026
INTERVENTIONAL
Conditions
Summary
ariessence is intended to be used as a viscous, leave-on solution designed for topical application to the face. It is intended to be used following non-medical cosmetic procedures, performed by licensed healthcare professionals to enhance comfort and maintain skin hydration. This study is designed to be a multi-center, post-market cosmetic evaluation of ariessence applied to the full face after an ablative laser procedure to evaluate improvements in procedure tolerability and improvements in the appearance of the skin, compared to an emollient control.
Eligibility
Inclusion Criteria7
- :Adults 40-65 70 years
- Glogau III-IV
- Fitzpatrick II-IV.
- Suitable for ablative laser
- non-smoker ≥ 3 years
- Willing to comply with post-procedure regimen
- patient reported outcome documentation, and photo documentation.
Exclusion Criteria6
- Fitzpatrick I or > IV,
- recent facial procedures (< 6 months)
- active skin disease
- pregnancy/lactation
- implanted devices
- history of keloids.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
To compare time to appearance-based recovery and subject satisfaction between ariessence and standard of care groups using standardized photographs and investigator/subject ratings for tolerability and satisfaction
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07718347